ICOSR 2017: The Prospects for New Drugs to Treat Schizophrenia

Mentions evenamide, ITI-007, MIN-101 and others.



Harvey was referring to MIN-101, a drug from Minerva Pharmaceuticals in Waltham, Massachusetts, that targets sigma 2 and 5-HT2A receptors. As described by Michael Davidson of Minerva in a therapeutics session on Sunday, March 26, two different doses of the drug reduced negative symptoms, with medium effects sizes. The study was conducted in patients with stable schizophrenia who had been taken off their antipsychotic medications in order to take MIN-101 as a monotherapy. There were no major side effects, and it was promising that positive symptoms and extrapyramidal symptoms did change for the study patients, which also argues that the improvements in negative symptoms were not secondary to improvements in positive or extrapyramidal symptoms. In reply to an audience member, Davidson conceded that it was possible that patients who had been on long-acting injectable antipsychotics before entering the trials still had enough in their systems to interfere with the interpretation of the results.

Looks like ITI-007 still means business.